BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

807 related articles for article (PubMed ID: 28976600)

  • 21. Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin.
    Dotson J; Elhamdani A; Petryna E; Jamil MO; Alsharedi M
    Int J Hematol; 2019 Mar; 109(3):351-355. PubMed ID: 30506467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with
    Schlenk RF; Weber D; Fiedler W; Salih HR; Wulf G; Salwender H; Schroeder T; Kindler T; Lübbert M; Wolf D; Westermann J; Kraemer D; Götze KS; Horst HA; Krauter J; Girschikofsky M; Ringhoffer M; Südhoff T; Held G; Derigs HG; Schroers R; Greil R; Grießhammer M; Lange E; Burchardt A; Martens U; Hertenstein B; Marretta L; Heuser M; Thol F; Gaidzik VI; Herr W; Krzykalla J; Benner A; Döhner K; Ganser A; Paschka P; Döhner H;
    Blood; 2019 Feb; 133(8):840-851. PubMed ID: 30563875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
    Sly N; Gaspar K
    Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
    Tollkuci E
    J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
    Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
    Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
    Stone RM
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
    Wang ES
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
    Tvedt TH; Nepstad I; Bruserud Ø
    Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Midostaurin in FLT3-mutated acute myeloid leukaemia.
    Das M
    Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
    [No Abstract]   [Full Text] [Related]  

  • 32. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.
    Marconi G; Giannini MB; Bagnato G; Simonetti G; Cerchione C; Mosquera Orgueira A; Musuraca G; Martinelli G
    Expert Opin Drug Saf; 2021 Jul; 20(7):791-799. PubMed ID: 33853481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
    Manley PW; Caravatti G; Furet P; Roesel J; Tran P; Wagner T; Wartmann M
    Biochemistry; 2018 Sep; 57(38):5576-5590. PubMed ID: 30148617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
    Döhner H; Weber D; Krzykalla J; Fiedler W; Wulf G; Salih H; Lübbert M; Kühn MWM; Schroeder T; Salwender H; Götze K; Westermann J; Fransecky L; Mayer K; Hertenstein B; Ringhoffer M; Tischler HJ; Machherndl-Spandl S; Schrade A; Paschka P; Gaidzik VI; Theis F; Thol F; Heuser M; Schlenk RF; Bullinger L; Saadati M; Benner A; Larson R; Stone R; Döhner K; Ganser A
    Blood Adv; 2022 Sep; 6(18):5345-5355. PubMed ID: 35486475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
    Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Midostaurin Gets FDA Nod for AML.
    Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Midostaurin: First Global Approval.
    Kim ES
    Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
    Roskoski R
    Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
    Schlenk RF; Kayser S
    Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.